Navigation Links
Chimerix Presents Data Highlighting Burden Of Care Associated With Current Antiviral Therapies In Stem Cell Transplantation
Date:9/21/2012

negatively impact both stem cell and organ transplant recipients.  CMX001 has demonstrated clinical activity in the prevention of CMV infection and preemption of AdV infection post-HSCT.

The data presented were derived from CMX001 Study 201*, Chimerix's Phase 2 study evaluating CMX001 for the prevention of CMV disease in HSCT recipients.  The subset of patients described above received placebo or an inactive, low dose of CMX001.

Chimerix is planning to explore further the potential benefit of CMX001 in efficacy and safety, and reducing the burden of care. Chimerix is initiating a Phase 3 clinical trial of CMX001 for the prevention of CMV infection in adult CMV seropositive HSCT recipients, in which all subjects will be followed through 24 weeks post-transplant.

About Chimerix and CMX001
Chimerix is developing novel oral antiviral therapeutics with the potential to improve outcomes for patients in multiple therapeutic areas, including transplant, oncology, acute care and global health.  The company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety compared with currently approved drugs. 

CMX001 is a novel, broad-spectrum, oral antiviral that inhibits dsDNA viruses, including CMV, AdV, BK virus and herpes simplex virus.  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV in HSCT recipients and is in Phase 2 development for the preemption and treatment of AdV infection.  To date, more than 800 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Chimerix has completed an End of Phase 2 meeting with the FDA and is preparing to initiate Phase 3 clinical development of CMX001 for the prophylaxis of CMV in HSCT recipients in early 2013.   

In addition to its co
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
2. Chimerixs Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study
3. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
4. Jennerex Presents Positive Clinical Data from Phase 2 Trial of JX-594 in Sorafenib-Refractory Liver Cancer Patients
5. Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
6. Mettler Toledo Presents In-depth Guidance to Comply with New USP Chapters 41 and 1251 on Balances Used for Quantitative Analysis in the Pharma QC Lab
7. Elevation Pharmaceuticals Presents Positive Phase 2b Results for EP-101 in COPD Patients at the European Respiratory Society Annual Congress
8. Informex Global Pharma Sourcing 2012 Presents Key Strategies & Insight For Business Success
9. Epigenomics Presents Significant Opportunities for Investment and Product Development, According to New Biotech Market Research
10. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 29, 2014 Electrodes ... potential which can be amplified to diagnose as ... electrodes used in medical devices facilitate the detection ... from muscle cells and neurons of the patients. ... utilize the radiofrequency alternating current to perform minimally ...
(Date:10/30/2014)... BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today reported financial ... "During the quarter, we achieved a key ... securing a partner to accelerate the development and commercialization of ... we do not have a commercial presence while also retaining ... the value of PIXUVRI for CTI and help us achieve ...
(Date:10/30/2014)... YORK , Oct. 29, 2014 ... growth through 2013 with the introduction of new ... well-covered in Vaccines: The World Market. The Kalorama ... covering specifically commercialized vaccines and developmental vaccines for ... not only individuals, but also entire communities from ...
Breaking Medicine Technology:Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 2Vaccines 2014: World Market Analysis, Key Players, Trends, Pediatric and Adult Segments 3
... (Nasdaq: UPI ), a medical device company ... treat voiding dysfunctions, announced today that David Kaysen, Uroplasty,s ... and CFO, will present the Company,s business strategy and ... Conference at 3:30  PM PDT on Tuesday, August 17, ...
... SPRING, Md., Aug. 16 The U.S. Food ... of the drug midodrine hydrochloride, used to treat ... required post-approval studies that verify the clinical benefit ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference 2FDA Proposes Withdrawal of Low Blood Pressure Drug 2FDA Proposes Withdrawal of Low Blood Pressure Drug 3
(Date:10/30/2014)... the DFG Research Center for Regenerative Therapies Dresden - ... for the first time the in vitro growth of ... mouse embryonic stem cells. Correct spatial organization of motor ... was observed., This study has been published online by ... on 30.10.2014 ., For many years Elly Tanaka and ...
(Date:10/30/2014)... Beach, Florida (PRWEB) October 30, 2014 ... Halloween visit to Pompano Beach firefighters, showing that you ... community. , Timothy met firefighters Tracey and Carl ... by Galuppiā€™s Restaurant and the Pompano Beach Chamber of ... outside the fire truck, letting Timothy wear his real ...
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager focused ... people save money through its innovative discount card program. ... in the new health care system, the Paramount Rx ... relationship between consumers, businesses and the pharmacy industry. ... today with medical costs is the rising price of ...
(Date:10/30/2014)... By Tara Haelle ... (HealthDay News) -- More than 100 genes have been ... new studies report. And researchers say they are ... overall that may contribute to the disorder. Autism ... by communication and social difficulties and repetitive behaviors. An ...
Breaking Medicine News(10 mins):Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 2Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 3Health News:4-year-old InstaKNOT CEO Honors Local Firefighters with Community Support 4Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3
... , CAMBRIDGE, Mass. , ... organization focused on advancing human health through innovation, today ... Business Innovation Research (SBIR) contract from the National Aeronautics ... develop nanoscale diagnostic technologies that facilitate whole health analysis ...
... from mice, scientists from Iowa and Iran have discovered a ... to be rejected by a recipient,s immune system. This strategy, ... 2010 print issue of The FASEB Journal ( ... cells. Once fused, the hybrid cells have DNA from both ...
... produces an extraordinary and dangerous poison. This is the only ... A study carried out at the University of Haifa has ... Has the almond tree developed a unique way of ... of Environmental and Evolutionary Biology and the Department of Science ...
... the process of diagnosing heart conditions. The portable ... with funding from the Engineering and Physical Sciences Research ... to its unprecedented sensitivity to magnetic fluctuations the device ... including heart problems in foetuses, earlier than currently available ...
... ... and downs of the decade. , ... Pennington, NJ (PRWEB) January 28, 2010 -- In good times and in bad, people ... Robinson, Inc., overall attitudes towards Super Bowl advertising have remained strongly positive throughout the economic ...
... 2010 ... information, many more products in an ever expanding market but “simplified buying for the ... ... -- 2010 marks the launch of Décor Grille’s new “ Security Direct ” web ...
Cached Medicine News:Health News:NASA selects DNA Medicine Institute's Nanoscale Diagnostics Technology for Phase II SBIR 2Health News:Stem cell breakthrough: Bone marrow cells are the answer 2Health News:The almond tree's secret weapon 2Health News:The almond tree's secret weapon 3Health News:Breakthrough heart scanner will allow earlier diagnosis 2Health News:Super Bowl Advertising, In Good Times And Bad 2Health News:Super Bowl Advertising, In Good Times And Bad 3Health News:Dcor Grille Leads into the Next Decade with its New Security Web Site 2
... Cement consists of a two ... bone cement liquid within a ... polyethylene bag,containing bone cement powder ... interiors of the blister pack,and ...
... Radiopaque Bone Cement consists of ... sterile,ampule containing bone cement liquid ... a sterile polyethylene bag,containing bone ... pouch. The interiors of the ...
A "doughy" type of bone cement intended for manual application....
... technology, such as a recessed scratch-resistant sapphire ... housings, this arthroscope has superior clarity and ... Steris and steam autoclaving or soaked in ... to fit ACMI, Wolf, Dyonics and Storz ...
Medicine Products: